Arcellx saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 61 to 73.
IBD's proprietary rating tracks share price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the top-performing stocks typically have an RS Rating north of 80 in the early stages of their moves. See if Arcellx can continue to show renewed price strength and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
Arcellx is not currently offering a proper buying opportunity. See if the stock goes on to build a sound pattern that could launch a new move.
Arcellx posted 0% earnings growth in the latest quarterly report. Sales increased -76%.
The company holds the No. 172 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Halozyme Therapeutics and Krystal Biotech are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
